Background. A national crisis of opioid-related morbidity, mortality, and misuse has led to initiatives to address the appropriate role of opioids to treat pain. Deployment of a guideline from the Centers for Disease Control and Prevention to reduce the risks of opioid therapy has raised substantial clinical and public policy challenges. The agency anticipated implementation challenges and committed to reevaluating the guideline for intended and
Introduction
A national crisis of opioid-related morbidity, mortality, and misuse has led to initiatives to address the role of primary care physicians and other prescribing clinicians. The 2016 release of the Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain outside of active cancer, palliative, and end-of-life care was intended to enhance patient and community safety by providing guidance on best clinical practices [1] .
As the guideline has been adopted, substantial challenges have emerged, including those related to appropriate opioid use in patients with acute pain following trauma and the 5 to 8 million patients [2] with chronic pain presently being managed on long-term opioid therapy (LTOT). Challenges in guideline implementation were anticipated, with the CDC explicitly committed to "evaluating the guideline to identify the impact of the recommendations on clinician and patient outcomes, both intended and unintended, and revising the recommendations in future updates when warranted" [1] . The purpose of this report is to discuss several challenges that have emerged for prescribing clinicians who treat patients with pain as a result of clinical guidance and policy actions based on the CDC guideline.
Methods
To identify and address these challenges, the American Academy of Pain Medicine Foundation convened a multidisciplinary panel of physician experts, reflecting a spectrum of clinical, research, and academic experience. In selecting invitees, foundation and physician leaders aimed to form a working group of sufficient size (12-15 members) and specifically sought a wide range of pertinent viewpoints and professional experience. The panel (Box A1) met in Chicago, Illinois, on December 9, 2017, to review the core recommendations of the CDC guideline, discuss relevant literature, and identify challenges related to guideline implementation. Deliberations continued via electronic communication, in two conference calls held in September 2018, and through several rounds of manuscript drafts. The panel reached consensus on proposals to address the challenges identified and recognized divergent opinions on some topics.
Importance of the CDC Guideline
The CDC guideline is aimed at improving opioid prescribing practices to ensure safe and effective chronic pain treatment while reducing the risk of opioid use disorder (OUD), overdose, and death. The 12 core recommendations of the CDC Guideline are shown in Box A2 [1] .
The panel commended many facets of the guideline, including clinical reminders to:
• know that opioids are not firstline therapy for chronic pain;
• discuss the risks, benefits, and availability of nonopioid treatments with patients; • establish and measure goals for pain and function;
• emphasize patient-centeredness and individualized care;
• evaluate risk factors for opioid-related harms specific to the individual patient; • avoid concurrent benzodiazepine and opioid prescribing;
• prescribe opioids only in needed quantities and durations;
• initiate opioids at the lowest effective dose with frequent followup and monitoring; • ensure opioids, when indicated, are part of a comprehensive, multimodal pain treatment plan; • use prescription drug monitoring programs and urine drug testing to monitor patient adherence to the treatment plan; • reduce opioid dose or taper and discontinue if risks outweigh benefits or if benefits do not outweigh harms; • arrange treatment for OUD if indicated.
One noted potential benefit of the guideline may be that fewer opioid-naïve patients begin LTOT and that those who do receive lower doses. While largely supportive of the guideline, the panel also identified implementation challenges with potential for untoward outcomes.
Guideline Implementation Challenges
The period following guideline release has seen clinical and policy issues that may have gone beyond what was originally intended by developers of the guideline. In particular, the appropriate role of regulatory and policymaking bodies, including public and private payers, requires clarification. The guideline was not meant to be prescriptive but, at times, has been implemented without flexibility, perhaps without full awareness of the guideline's precise content and intent. One reason may be that important clarifying information located in less prominent sections of the guideline may be overlooked or underappreciated by readers focused on the 12 recommendations.
Challenges caused by guideline misapplication identified by the panel include:
• inflexible application of recommended ceiling doses or prescription durations as hard limits; • abrupt opioid taper or cessation in physically dependent, opioidtreated patients without regard for CDC emphasis on empathically reviewing benefits and risks of continued high-dosage therapy and working collaboratively with patients on a tapering plan; • lack of availability and coverage for recommended comprehensive, multimodal pain care; • difficulty of OUD diagnosis and barriers to accessing evidencebased OUD treatment; • underutilization of naloxone;
• incomplete data in reporting of overdose death statistics.
The challenges are further described in Box A3 and in the detailed discussion that follows.
Limits on Dosages
Concern was expressed that some policy-makers are interpreting the CDC daily dosage thresholds as firm limits without regard to CDC advice to individualize treatment and work with patients. Policies to restrict daily dose have been enacted in several states. Also, private insurers have limited coverage to control and limit dose [3] .
One recent policy proposal, ultimately tempered, would have capped opioid prescription coverage through the Centers for Medicare and Medicaid Services (CMS) at 90 morphine milligram equivalents (MME) per day with the stated goal of concordance with the guideline [4] [5] [6] [7] . The final policy, instead, requires a pharmacist who receives a prescription above the threshold to confirm it with the doctor and document the discussion [8] . In comments explaining its decision to hold back implementing hard 90 MME safety thresholds for opioids, CMS reported that [9] :
• physician groups expressed concerns about the risks for patients of abrupt discontinuation or rapid taper of high doses; • patients sent hundreds of letters describing fear of abrupt reduction or discontinuation of their long-time medication regimens "with sometimes extremely adverse outcomes, including depression, loss of function, quality of life, and suicide" [9] ; • CMS plan sponsors and other organizations expressed support for CMS's goal to aggressively address opioid overuse but requested to set their own MME thresholds.
This last point suggests that some plan sponsors may make dosage a benchmark without fully considering the CDC guideline's intent to individualize treatment and work with patients.
Some panel members believed that the CDC dosage thresholds could remain protective if clinicians were allowed to individualize decisions after evaluating patient factors that predict a higher risk of opioid-related death, overdose, and other injuries. Such factors for evaluation include pain etiology, response to therapy, medical comorbidities, co-occurring psychological disorders, past or previous substance use problems, history of opioid misuse, and concomitant benzodiazepine use [1] .
The panel agreed that any legislative, regulatory, or payer policies enacted should make provisions for appropriately selected and monitored patients who need and benefit from longer duration or higher dosage.
Opioid Taper or Cessation
Opioids may be tapered for several reasons, including inadequate analgesia or intolerable side effects, resolution of pain, overall poor quality of life, or evidence of a pattern of misuse or OUD.
There was concern that daily MME thresholds in CDC Recommendation 5 are being rigidly applied in some cases without adequate attention to the needs of established or inherited patients who are already on LTOT. Indeed, the guideline allows some flexibly when it further states:
Established patients already prescribed high dosages of opioids (90 MME/d), including patients transferring from other clinicians, should be offered the opportunity to reevaluate their continued use of opioids at high dosages in light of recent evidence regarding the association of opioid dosage and overdose risk. For patients who agree to taper opioids to lower dosages, clinicians should collaborate with the patient on a tapering plan [1] .
Although the guideline does not support abrupt noncollaborative opioid taper or cessation in patients on a dose above a given target (90 MME or other), certain panel members observed that some clinicians, policymakers, managed care administrators, and pharmacy benefit managers have inferred an enforceable dose ceiling as a de facto mandate [3, 10, 11] . Panelists described patients who request providers to assume responsibility for opioid prescribing after involuntary dismissal from another practice without weaning or a treatment plan for pain or OUD [10] . In addition, in an atmosphere of heightened enforcement, clinicians and dispensing pharmacists may harbor professional concerns about potential sanctions connected to prescribing patterns [10] .
The panel held that, whenever possible, patient engagement is preferred during opioid taper, as suggested by the CDC guideline [1] . Some on the panel expressed concern that some patients who are discontinued from opioids abruptly or without their consent may go elsewhere to a licit or illicit channel [12] . Separately, concern was raised regarding patient deaths during or soon after nonconsensual taper, events reported primarily in anecdotes or small case series describing suicidal ideation and self-directed violence, medical deterioration, and, in some instances, procurement of illicit market opioids [13] [14] [15] [16] . The rate of these events is not known, nor is it clear that nonconsensual taper was the main or only cause of the adverse outcomes. A further complication is the lack of validated tapering protocols in patients on opioids for chronic pain, although several guides to providing safe and comfortable opioid tapering have been published [13, 17] .
Although gradual and supported taper are believed to be associated with improved pain outcomes, the evidence base on opioid dose reduction and discontinuation is still evolving. A recent systematic review found low-quality but consistent evidence suggesting that several types of opioid tapers may be effective and that pain, function, and quality of life may improve for some patients with consensual opioid dose reduction, especially with the support of a multidisciplinary team [13] . A recent study found that 62% of patients remained in a voluntary, patient-centered opioid taper over four months, with median decreases in morphine equivalent daily dose from 288 mg to 150 mg [18] . Whereas a highly supported, monitored taper can improve pain or quality of life in a number of patients, a subset may experience worsened pain.
The panel was unanimous that abrupt cessation of opioids (and sedatives) is medically risky and outside the intent of the CDC guideline. Furthermore, it is unacceptable practice to abruptly dismiss physically dependent patients from care without an adequate plan for pain or OUD treatment follow-up except in unusual circumstances, such as diversion. The CDC guideline provides detailed discussion of the need for gentle and often slow tapers [1] ; however, some prescribers may be unaware of this message. Recommendation 7 supports a decision on the basis of individualized evaluation of harm vs benefit and does not mandate taper to any target. Therefore, the panel affirmed that providers should offer a gradual taper while instituting alternative pain treatments or OUD treatment as needed, or else refer the patient to a provider willing to provide these services [2, 19] .
Discussion of the potential harms of abrupt discontinuation should not be taken as blanket endorsement for continuation. Given that the benefits of chronic opioids often diminish over time while the risks do not, a decision to discontinue LTOT may be reasonable. Some panel members favored a general opioid dose reduction approach, given the association between higher doses and adverse outcomes [1] . However, when low-risk patients demonstrate improved comfort and function in the absence of adverse effects and aberrant behaviors, some panel members felt that there is little to be gained by eliminating opioids, and there is the potential for harm [20] .
Although continuing treatments that are both ineffective and hazardous is unwarranted, the panel also agreed that opioid cessation may not be the most appropriate target when patients maintained on high opioid doses for years have developed what has been called "complex persistent dependence," an intermediate gray zone between physiologic dependence and OUD [20] . These patients may need to be transitioned to buprenorphine or reduced full-agonist opioid doses to improve safety and, in some cases, function and quality of life. Integrating behavioral health and nonopioid pain therapies first may enhance the therapeutic relationship and prepare the patient to manage pain before initiating an opioid taper or dose reduction. In many instances, a re-evaluation of the underlying causes of the presenting pain complaint and subsequent successful treatment integration may facilitate opioid reduction or discontinuation. Absent aggravating circumstances, opioid taper and management of behavioral, mental, and substance use problems need not occur immediately, unless current medications pose imminent risk [21] . In summary, the panel emphasized the CDC recommendation on gradual and supported taper with patient engagement and cautioned that clinicians should not interpret opioid reduction messages as the need to automatically and immediately reduce or stop LTOT or dismiss patients with risk factors from care.
Limits on Prescription Durations
The panel endorsed the CDC recommendation to limit any medically necessary opioid prescriptions to the shortest necessary duration for acute pain and to prescribe the lowest effective dose. Furthermore, although the guideline is not intended to address postoperative pain, the panel noted its potential impact on pain treatment after surgical procedures. Evidence shows that excessive quantities of opioid have often been given for acute pain when a small supply would be sufficient, contributing to misuse or diversionary risk [22, 23] . Therefore, the panel agreed that prudent prescription durations may reduce the risk of redistribution and diversion.
Although CDC Recommendation 6 states that a prescription duration longer than seven days will rarely be needed for acute pain, the panel noted that accommodation must be made for patients who need longer duration of opioid analgesia. Concern was raised by some panel members that if the seven-day duration limit were inflexibly applied as a hard limit, patients with severe pain persisting more than a week and not controlled by nonopioid therapies could lack access to needed analgesia. Furthermore, access challenges encountered by certain patients (e.g., newly diagnosed cancer patients and elderly, rural, or other isolated patients) also must be considered.
The issue of prescription duration limits is underscored because states began passing legislation to limit opioid prescriptions in 2016, and by April 2018, 28 states had enacted such legislation, most frequently limiting prescription durations, with a few also setting daily dosage limits [11] . States do allow some common exceptions for chronic, cancer, and palliative pain, treatment of substance use disorder (SUD), and, importantly, professional judgment of the prescribing clinician, as long as the rationale is carefully documented in the medical record [11] . These exceptions were deemed important for all clinicians, payers, policy-makers, and other influences of prescribing practices to note.
Although the CDC guideline specifically excludes cancer treatment, palliative care, and end-of-life care and states that postoperative pain management is beyond its scope, concern was expressed that misapplication of Recommendation 6 could promote unintended "drift" into an increasing reluctance by providers to prescribe opioids for these indications [19] and by pharmacists to fill prescriptions. Overall, the panel supported reducing opioid prescriptions for acute pain whenever possible and noted that Enhanced Recovery After Surgery (ERAS) pathways, a team-based approach that emphasizes pain control through multimodal analgesia and limited reliance on opioids, have reduced opioid use and improved outcomes [24] .
Limited Comprehensive, Multimodal Pain Care
The CDC guideline and panelists agreed that if a clinician determines that the potential benefits of opioids outweigh risks, their prescription should be part of a comprehensive, multidisciplinary, multimodal treatment plan in which patients are assessed and closely monitored [1] . It was noted that clinical experience indicates that nonopioid therapies that have previously "failed" can succeed when tried again with careful clinical evaluation and follow-up using a comprehensive, multimodal approach. Unfortunately, integrated comprehensive pain care models (i.e., multimodal, multidisciplinary, and interdisciplinary rehabilitation programs) are neither widely available nor sufficiently reimbursed despite demonstrated long-term cost and health care utilization advantages [25, 26] . Telemedicine that includes access to and payment for physicians and other health care providers may prove useful for reassessment if widely integrated into workflows and reimbursed [27, 28] .
Difficulty of Diagnosing and Treating Opioid Use Disorder
The panel noted that it can be challenging to distinguish incipient OUD and complex persistent dependence from increasing pain due to the underlying pain condition, worsening pain-related distress due to exacerbation of medical, psychological, or social factors, or opioidinduced hyperalgesia. However, it was also noted that OUD can be a fatal disease whose recognition is vital to instituting necessary treatment; therefore, clinicians who prescribe LTOT should be required to demonstrate a basic knowledge of OUD diagnosis and treatment. This is especially important where specialty consultation in addiction medicine is inaccessible.
A feature of any SUD is continued use of a substance despite harm. Self-report of improvement with opioids is problematic in the presence of physical dependence or OUD and may be unreliable in the absence of improved function and quality of life [29] . Thus, patients' desire to continue opioids cannot always be a reliable guide to appropriate treatment; that is, tapers cannot always be consensual [30] . "Adverse selection" [31] is a principle describing the clinical phenomenon in which patients at risk for worse outcomes due to mental disorders and SUDs are the ones most likely to receive opioids and at higher doses [32] [33] [34] . Further complicating clinical decisions regarding opioid medications, chronic pain is closely intertwined with comorbid mental health and SUDs, as shown by a body of research:
• Chronic pain was reported by 87% of 589 participants with unhealthy substance use identified in primary care [35] .
• An analysis of opioid-related fatalities in Medicaid recipients showed that most (61.5%) had chronic pain and were significantly more likely than those without chronic pain to have been diagnosed with depression, anxiety, or drug use, though not OUD, during the last year of life [36] .
• Other research indicates that pain increases the relative risk of developing prescription-related OUD [37] . However, the majority of patients on opioids for chronic pain do not develop an OUD.
• Mental health conditions are among the patient characteristics associated with "unintended prolonged opioid use," which is characterized by use of opioids beyond the intended short-term course, for example, for minor surgery [38] .
• Treatment-resistant depression is more common in people on opioid therapy, and patients with mental health comorbidities are more likely to receive opioids [32, 39] .
• Epidemiologic and functional imaging studies suggest that chronic pain and mental health disorders have a bidirectional relationship due in part to shared neural mechanisms [40] .
When patients are clearly endangered or harmed by their opioid treatment, clinicians are legally and ethically obliged to work to mitigate the situation. Yet panelists noted that patients who most need an opioid taper may be least open to discussion or consensual taper and may react belligerently.
Although the CDC recommends medication-assisted treatment for OUD, the panel discussed the possibility that a patient at high risk for opioid-related harm who has pain and physical dependence but no diagnosed OUD might also benefit from buprenorphine as a continuing treatment or bridge to eventual opioid discontinuation. Many panel members shared a perspective based on clinical observation that a subset of patients may be candidates for off-label buprenorphine if the patients are at heightened risk of dismissal from pain care, even though they may not meet criteria for the FDA-approved indication of OUD. The possibility that a trial of buprenorphine in medication-assisted treatment doses may be a safer option for these patients is suggested by clinical experience reported by experts [20] and mostly single-arm, poor-quality studies with variable follow-up rather than clinical trials [41, 42] .
Others on the panel emphasized the need to continue to consider and diagnose OUD in such patients when appropriate, to consider opioid taper to the lowest dose possible in consensual fashion, or both. Thus, although it was noted that certain patients who are not showing benefit from opioids tolerate opioid taper poorly or not at all, no consensus was reached on how to define or treat this subset of patients. Supporting literature is inconclusive. In people with prescription OUD, a voluntary taper was less successful than ongoing maintenance with buprenorphine in two high-quality randomized controlled trials [43, 44] .
Additionally, insurance will sometimes not authorize or reimburse for buprenorphine formulation preparations indicated for OUD in patients lacking this diagnosis. The panel discussed the ethical challenge if a clinician should falsely apply a clinical diagnosis of OUD in order to meet payment or other criteria imposed by payers and health systems. It was noted by some that patients may experience stress or social stigma resulting from the application of an OUD diagnosis for which they do not qualify. The panel agreed that the use of buprenorphine for care of patients with a history of opioid receipt for pain requires scientific attention and policy deliberation. All panelists concurred regarding the need to continue to mitigate risk and conduct monitoring in conjunction with buprenorphine treatment.
Naloxone Underutilization and Mortality Statistics
The panel agreed with the CDC emphasis on naloxone for patients with risk factors for opioid overdose and further expressed consensus that naloxone is insufficiently available. States have passed laws intended to increase naloxone distribution and reduce liability for laypersons, first responders, and pharmacists [45, 46] . Yet high costs and variable access remain due to factors involving the roles of manufacturers, state governments, private and public insurers, pharmacy chains, and pharmacy benefit managers [45, 47] .
Underutilization of naloxone also results in part from uncertainty as to who should receive it. Polypharmacy, mental disorders, SUDs, and high-dose opioids are CDC-recognized risk factors that suggest naloxone coprescription [1] . Yet most opioid-related deaths are attributable to illicitly obtained analgesics and recreational drugs, such as heroin [48] [49] [50] . Recent data from Massachusetts and Washington State indicate that among persons suffering an opioid poisoning event, less than 50% had received a prescription recently before the overdose death [51, 52] . In addition, the majority of opioid fatalities involve multiple substances, particularly sedatives such as benzodiazepines [51, 53] .
The confusion around sources of diverted opioids may be exacerbated by media messages that foster the false belief that most opioids are misused by people who were prescribed them. In fact, the National Survey on Drug Use and Health reports that only 37% of adults who misused opioids had a prescription, and 53% obtained their most recent misused opioids from friends or relatives [54] . The panel noted the association of SUDs with social problems: For example, misuse and OUDs are most common in adults who are uninsured, unemployed, poor, or suffering from behavioral health problems [55] . However, the panel further emphasized that no one is immune from the ravages of SUD.
Although the panel did not achieve consensus on a proposal regarding mortality statistics, some members discerned a need to collect, conduct, and report more complete, accurate opioid-related death statistics to facilitate the understanding of differences in lethality of specific licit and illicit opioid agents to better target overdose death reduction initiatives, including naloxone prescription. This would include efforts to examine and quantify the contribution of diverted prescription opioids to the current opioid harm crisis.
Panel Proposals
The panel devised consensus proposals (Box A4) to increase guideline clarity and usefulness and to reach the regulators, policy-makers, and payers who influence guideline implementation. The panel further seeks to add to the discussion and evidence base that will inform future iterations of the guideline. An overarching principle for the panel was to support efforts to reduce the overprescribing of opioids that has led to opioid-related patient and societal problems while at the same time using opioids in an appropriate and reduced-risk fashion for acute pain and in a small subset of patients with chronic pain. editing this article in accordance with the guideline of the International Committee of Medical Journal Editors (ICMJE) defining the role of authors and contributors and received payment for services from the foundation.
Box A2. Centers for Disease Control and Prevention recommendations for prescribing opioids for chronic pain outside of active cancer, palliative, and end-of-life care Determining When to Initiate or Continue Opioids for Chronic Pain 1. Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.
2. Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how therapy will be discontinued if benefits do not outweigh risks. Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety.
3. Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy.
Opioid Selection, Dosage, Duration, Follow-up, and Discontinuation 4. When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/ long-acting (ER/LA) opioids.
5. When opioids are started, clinicians should prescribe the lowest effective dosage. Clinicians should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when increasing the dosage to 50 morphine milligram equivalents (MME) or more per day, and should avoid increasing the dosage to 90 MME or more per day or carefully justify a decision to titrate dosage to 90 MME or more per day.
6. Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater a quantity than needed for the expected duration of pain severe enough to require opioids. Three days or less will often be sufficient; more than seven days will rarely be needed.
7. Clinicians should evaluate the benefits and harms with patients within one to four weeks of starting opioid therapy for chronic pain or of dose escalation. Clinicians should evaluate the benefits and harms of continued therapy with patients every three months or more frequently. If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids.
Assessing Risk and Addressing Harms of Opioid Use 8. Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms. Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages ( 50 MME/d), or concurrent benzodiazepine use, are present.
9. Clinicians should review the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP) data to determine whether the patient is receiving opioid dosages or dangerous combinations that put him or her at high risk for overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain, ranging from every prescription to every three months.
10. When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.
11. Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible.
12. Clinicians should offer or arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder.
Box A3. Challenges identified in implementing the CDC guideline in clinical practice
Box A4. Panel proposals addressed to government and private funders of research, public and private payers, and makers of health care law, regulation, and policy
• There is confusion in practice as to whether daily opioid dosage ceilings are to be universally applied, regardless of previous opioid exposure.
• Daily dosage ceilings, if implemented as hard limits, may promote abrupt dose reductions in patients on high doses, which risks withdrawal symptoms, hyperalgesia, and self-medication with more hazardous alternatives.
• Preferred practices regarding dosage ceilings are set as policy when payers make coverage and reimbursement decisions.
• The patient welfare consequences of an abrupt vs gradual and supported opioid tapers have not been clearly elucidated.
• A lack of access to resources has impeded a move toward integrated, multimodal, and comprehensive pain care, as espoused in the guideline.
• Naloxone co-prescribing is underutilized due to confusion around proper use and barriers to access.
CDC ¼ Centers for Disease Control and Prevention.
Appropriate Opioid Tapering
Facilitate interprovider communication and full reevaluation of harms and benefits in the care of patients on opioids who are inherited from other practices.
Produce validated tapering protocols for patients on opioids for chronic pain.
Alert clinicians that it may be medically risky to abruptly discontinue opioids and other controlled substances in a patient who is physically dependent without psychosocial management, focused care, gradual taper, and/or adjuvant therapies to treat withdrawal symptoms.
Avoid misinterpreting the guideline by insisting on opioid reduction or cessation in pain conditions or treatment settings where opioid use may still be warranted (e.g., palliative care, severe chronic pain when benefits outweigh risks) as the guideline does not proscribe opioid use in these situations.
Prescription Dose and Duration Limits
Clarify the appropriate clinical application of the recommended dosage thresholds by acknowledging previous opioid exposure and patient variability in risk factors for opioid-related overdose.
Fund more research to determine optimal dosage thresholds and improve understanding of potential differences in opioid metabolism and response.
Fund more research to determine optimal prescription duration for acute pain care.
Toward Comprehensive, Multimodal Pain Care
Support a sufficient reimbursement and coverage structure to permit safe, effective pain treatment, including primary care access to psychological and physical treatments and comprehensive pain management services when indicated.
Embrace the opportunity to work with insurance payers who exhibit interest in shifting to new reimbursement strategies that prioritize comprehensive, multimodal pain care.
Support clinician training in a full range of available pain treatments and a team-based approach to pain care to include relevant clinic staff and pharmacists.
Disseminate programs to enhance prescriber competence in safer opioid prescribing.
In addition to dollars currently earmarked to fight the opioid problem, allocate funding to better study and support more comprehensive, multimodal pain care.
Acknowledge and reimburse some forms of telemedicine and virtual visits for follow-up and reassessment.
Protecting Patients from Unintended Consequences
Advise clinicians to avoid patient abandonment and that opioid failure does not preclude pain treatment.
Consider revision to federal, state, or payer policies that treat opioid dose as the primary benchmark for quality of care without adequate attention to maintaining pain control through alternative pain therapies.
Revise policies aimed at promoting dose tapering to ensure patient engagement, when possible, careful reevaluation of harms vs benefits, and access to care.
Require the formal tracking of patient-level outcomes, favorable and unfavorable, of any interventions focused on prescription reductions pursued by payers or regulators.
Toward Naloxene and OUD Treatment Optimization
Address access and cost barriers to naloxone distribution.
Support research and policy deliberation on how best to serve the patient subgroup that poorly tolerates an opioid taper but lacks a formal OUD diagnosis, including clarifying the roles of opioid taper and possible buprenorphine administration.
Facilitate a clinic team focus with delegation of tasks to support staff to optimize both OUD and pain treatment.
